Remarkably, IL-6 is able to regulate metallothionein expression (177)
By blocking NNMT activity, it increases critical cellular metabolites (SAM, NAD) that drive downstream increases in energy expenditure and metabolic health 1-4
Kuroda S, Usui K, Sanjo H, et al
This is a critical advantage for individuals who want to manage body composition without the challenge of increased hunger that can occur with growth hormone-based approaches
Interventions: VK2735 Primary Outcome Measure: Percentage change in body weight from baseline for participants receiving VK2735 after 78 weeks of treatment Time Frame: 78 weeks Study Details Source VK2735 for Weight Management Type 2 Diabetes Phase 3 (VANQUISH 2) Sponsor: Viking Therapeutics Goal: This is a phase 3, multicenter, 78-week randomized, double-blind, placebo-controlled, parallel arm study that will evaluate the weight loss efficacy as well as safety, tolerability, pharmacodynamic effects, and pharmacokinetics of VK2735 in adults with Type 2 Diabetes who are obese or overweight